ANDA Submission Consulting
Reduce ANDA submission timelines and operational costs while maintaining expert regulatory oversight.
Accelerate ANDA Development with Regulatory Expertise and AI-Driven Efficiency
Successful ANDA submissions require more than technical documentation; they require regulatory strategy, submission excellence, and a deep understanding of FDA expectations.
ProPharma combines regulatory expertise with an AI-enabled submission platform to help generic drug sponsors streamline ANDA preparation, reduce operational burden, and accelerate submission readiness without compromising quality or compliance.
From first-time filers to established generic manufacturers, we provide the strategic guidance, technical expertise, and scalable support needed to move confidently from development to approval.
The ProPharma Difference: Expertise Enhanced by Innovation
Successful ANDA submissions require more than speed. They demand regulatory expertise, scientific rigor, and a clear understanding of FDA expectations.
Our proprietary approach to generic drug development combines experienced regulatory professionals with a novel AI-driven approach designed to improve efficiency without compromising quality. Our technology helps streamline document development, enhance consistency, and reduce manual effort, while our experts provide the strategic guidance, scientific review, and regulatory oversight needed to support submission success.
This expert-led, AI-enabled model helps sponsors:
- Accelerate submission timelines
- Improve consistency and quality across application components
- Reduce operational burden on internal teams
- Scale submission activities more efficiently
- Maintain confidence in regulatory compliance and submission readiness
Backed by former FDA professionals, CMC specialists, regulatory strategists, medical writers, and publishing experts, our team delivers the expertise and innovation needed to navigate ANDA submissions with greater speed.
Comprehensive ANDA Submission Support
From development planning through FDA review and approval, our team provides end-to-end support across the ANDA lifecycle.
Regulatory Strategy and Submission Planning
A successful ANDA begins with a clear regulatory strategy. Our experts help sponsors identify risks early, align development activities with FDA expectations, and establish an efficient path to submission.
Services include:
- Regulatory pathway assessment
- ANDA development strategy
- FDA regulatory intelligence
- Gap assessments and readiness evaluations
- Submission planning and risk mitigation
ANDA Authoring, Publishing, & Submission Management
Our team supports the preparation, review, compilation, and publishing of high-quality ANDA submissions designed to facilitate efficient FDA review.
Services include:
- Technical and scientific writing
- Submission-ready document development
- Content review and quality control
- Submission compilation and management
- eCTD publishing support
CMC and Bioequivalence Support
ProPharma provides integrated technical support across CMC and bioequivalence activities, helping sponsors develop, document, and present critical data required for ANDA success.
Services include:
- CMC strategy and documentation
- Drug substance and drug product support
- Manufacturing and facility information
- Bioequivalence strategy
- Technical data review and regulatory assessment
- Submission integration and quality review
FDA Review, Deficiency Response, & Lifecycle Management
Our support extends beyond submission. We help sponsors navigate FDA interactions, respond to agency requests, and manage post-submission activities through approval and beyond.
Services include:
- FDA correspondence management
- Information request responses
- Deficiency response preparation
- Complete Response Letter (CRL) remediation
- Post-approval regulatory support
- Lifecycle CMC and submission management
Supporting Generic Drug Sponsors Across the Product Lifecycle
Our team of expert regulatory consultants supports organizations at every stage of generic drug development, including:
- Emerging pharmaceutical companies
- Generic drug manufacturers
- Specialty pharmaceutical organizations
- Contract development and manufacturing organizations (CDMOs)
- Global companies entering the US market
Whether you need support for a single submission or an ongoing regulatory partner, our team can scale to meet your needs.
Why Partner with ProPharma?
Successful ANDA submissions require the right combination of expertise, strategy, and execution.
Sponsors choose ProPharma because we offer:
- Deep FDA and generic drug expertise
- Former FDA professionals and industry leaders
- Integrated regulatory, CMC, and submission capabilities
- Proprietary AI-enabled efficiencies with expert oversight
- Flexible support models tailored to your organization
- End-to-end support from planning through approval
Our team helps sponsors reduce regulatory risk, improve operational efficiency, and accelerate the path to approval.
Ready to Accelerate Your ANDA Submission?
Whether you are preparing your first ANDA or seeking a more efficient approach to managing submission volume, ProPharma can help. Connect with our Regulatory Sciences experts to discuss your program, timeline, and regulatory objectives.
ProPharma: The World's Leading Regulatory Consultancy
Contact us today to discuss your case and learn how our experts can strengthen your ANDA submission increasing efficiency and reducing the costs of application development.
News & Insights
November 16, 2026
Responsible AI in Medical Information: Safety, Ownership and Oversight
Explore the responsible adoption of AI in medical information, emphasizing safety, accountability, and the importance of human oversight in AI workflows.
November 9, 2026
Do You Need an LPPV in the Nordic Countries?
Explore the importance of local pharmacovigilance expertise in the Nordic countries, understanding compliance and enhancing safety management for marketing authorization holders.
July 8, 2026
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...
ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.
June 18, 2026
ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...
ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
November 2, 2026
Restoring Inspection Readiness and Data Integrity Following a CRO Transition
A CRO transition can uncover critical gaps in clinical trial oversight, documentation, protocol deviation management, and inspection readiness. When monitoring records are incomplete and outstanding...
October 20, 2026
Accelerating Clinical Trial Activation Across Latin America
Launching clinical trials across multiple countries requires navigating varying regulatory requirements, site contracts, translations, import/export processes, and site engagement activities, all...
September 18, 2026
Flexible Resourcing Without Limits: Scaling Capabilities Across the Development ...
Development complexity doesn’t increase in a straight line. As programs progress from discovery through Phase III, submission, and post-approval, demands for medical writing, biometrics, clinical...
December 2, 2026
Beyond the Buzz: Leveraging Community Management to Enhance Medical Information
Patients, caregivers, and healthcare professionals are increasingly turning to digital channels to seek information, share experiences, and discuss treatments. Join this webinar to explore how...
November 12, 2026
Empowering Sites, Engaging Patients: Strategies to Improve Clinical Trial Performance
Sites are being asked to do more than ever before while balancing increasing trial complexity, patient expectations, and operational demands. Join this webinar to explore how flexible, integrated...
News & Insights
November 2, 2026
Restoring Inspection Readiness and Data Integrity Following a CRO Transition
A CRO transition can uncover critical gaps in clinical trial oversight, documentation, protocol deviation management, and inspection readiness. When monitoring records are incomplete and outstanding...
September 18, 2026
Flexible Resourcing Without Limits: Scaling Capabilities Across the Development ...
Development complexity doesn’t increase in a straight line. As programs progress from discovery through Phase III, submission, and post-approval, demands for medical writing, biometrics, clinical...
November 12, 2026
Empowering Sites, Engaging Patients: Strategies to Improve Clinical Trial Performance
Sites are being asked to do more than ever before while balancing increasing trial complexity, patient expectations, and operational demands. Join this webinar to explore how flexible, integrated...